November 29, 2016 - By Nellie Frank
Douglas Michels, President & CEO of Orasure Technologies Inc, in an insider selling trade made a sale of 30,893 shares whose amount is estimated to be $278,711 at average stock price of $9.0. A Form 4 at your disposal for a review here made public this sale activity. It was made public on November 28, 2016 and filled with Washington-based Security and Exchange Commission. At the moment, Douglas Michels owns 731,898 shares which are equivalent to precisely 1.39% of the company’s total market cap.
Out of 5 analysts covering OraSure Technologies (NASDAQ:OSUR), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $10 is the highest target while $8 is the lowest. The $8.67 average target is 1.29% above today’s ($8.56) stock price. OraSure Technologies has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was maintained by Mizuho with “Buy” on Thursday, November 5. The company was maintained on Wednesday, August 24 by Canaccord Genuity. The rating was downgraded by BTIG Research to “Neutral” on Monday, September 19. Raymond James downgraded the stock to “Market Perform” rating in Monday, June 13 report. Jefferies maintained the stock with “Buy” rating in Thursday, August 4 report.
Insitutional Activity: The institutional sentiment decreased to 1.06 in Q2 2016. Its down 0.46, from 1.52 in 2016Q1. The ratio dropped, as 11 funds sold all OraSure Technologies, Inc. shares owned while 39 reduced positions. 25 funds bought stakes while 51 increased positions. They now own 43.86 million shares or 2.62% more from 42.75 million shares in 2016Q1.
Parametric Associate Ltd Liability Com owns 69,480 shares or 0% of their US portfolio. Campbell & Invest Adviser Lc holds 0.56% of its portfolio in OraSure Technologies, Inc. (NASDAQ:OSUR) for 18,806 shares. Healthinvest Prtnrs Ab accumulated 1.29% or 475,771 shares. Janney Montgomery Scott Limited Company accumulated 18,824 shares or 0% of the stock. Shikiar Asset Mgmt has 22,500 shares for 0.06% of their US portfolio. Argyle Capital Management, a Pennsylvania-based fund reported 35,275 shares. Bb&T has 0% invested in the company for 11,053 shares. The Connecticut-based Tudor Investment Corporation Et Al has invested 0.01% in OraSure Technologies, Inc. (NASDAQ:OSUR). Springbok Capital Mngmt Lc last reported 0.02% of its portfolio in the stock. Ubs Asset Americas Incorporated last reported 41,396 shares in the company. Piermont Cap has 0.55% invested in the company for 357,204 shares. Alliancebernstein L P accumulated 0% or 271,946 shares. State Street has 0% invested in the company for 1.04 million shares. Swiss Financial Bank accumulated 106,600 shares or 0% of the stock. Blackrock Invest Lc accumulated 215,332 shares or 0% of the stock.
Insider Transactions: Since August 5, 2016, the stock had 0 buys, and 5 insider sales for $1.42 million net activity. Another trade for 22,131 shares valued at $197,567 was sold by KUNA MARK L. $205,525 worth of OraSure Technologies, Inc. (NASDAQ:OSUR) shares were sold by Michels Douglas A. 26,308 shares with value of $217,722 were sold by Patrick Charles W on Friday, August 5. $216,000 worth of OraSure Technologies, Inc. (NASDAQ:OSUR) shares were sold by JERRETT JACK E.
About 479,707 shares traded hands or 4.56% up from the average. OraSure Technologies, Inc. (NASDAQ:OSUR) has risen 21.99% since April 25, 2016 and is uptrending. It has outperformed by 15.98% the S&P500.
OraSure Technologies, Inc. is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The company has a market cap of $473.55 million. The Firm also makes and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It has a 27.79 P/E ratio. The Company’s diagnostic products include tests, such as OraQuick Rapid HIV Test, OraQuick In-Home HIV Test, OraQuick HIV Self-Test, OraQuick HCV Rapid Antibody Test, OraQuick Ebola Rapid Antigen Test, OraSure QuickFlu Rapid Flu A&B Test, OraSure Collection Device, Molecular Collection Systems, Cryosurgical Systems (Skin Lesion Removal Products), Immunoassay Tests and Reagents, Western blot HIV-1 Confirmatory Test and Q.E.D.
According to Zacks Investment Research, “OraSure Technologies, Inc. is the market leader for oral fluid diagnostics. The Company develops, manufactures, and markets medical devices and diagnostic products for use by insurance companies, public health agencies, clinical laboratories, physicians’ offices, and workplace sites.”
Analysts await OraSure Technologies, Inc. (NASDAQ:OSUR) to report earnings on February, 1. They expect $0.05 earnings per share, down 37.50% or $0.03 from last year’s $0.08 per share. OSUR’s profit will be $2.77M for 42.80 P/E if the $0.05 EPS becomes a reality. After $0.11 actual earnings per share reported by OraSure Technologies, Inc. for the previous quarter, Wall Street now forecasts -54.55% negative EPS growth.
More recent OraSure Technologies, Inc. (NASDAQ:OSUR) news were published by: Finance.Yahoo.com which released: “OraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market ..” on November 28, 2016. Also Fool.com published the news titled: “Why OraSure Technologies, Inc Rose Today” on August 29, 2016. Fool.com‘s news article titled: “Why OraSure Technologies, Inc is Jumping Today” with publication date: August 24, 2016 was also an interesting one.
OraSure Technologies, Inc. (OraSure), incorporated on May 5, 2000, is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Firm also makes and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. The Company’s diagnostic products include tests that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community organizations and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. It sells over-the-counter (OTC) cryosurgical products to clients in North America, Europe, Central and South America, and Australia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Nellie Frank